Overall, EGFR/ALK profiling was significantly more often unfeasible in squamous cell carcinoma (17.5%, or 28 of 160 patients) than in non-squamous cell carcinoma (10.4%, or 60 out of 578 patients). This evidence concerns the gene EGFR and squamous cell carcinoma.